BioInvent International AB (publ) (STO:BINV)

Market Cap	2.28B
Revenue (ttm)	60.80M
Net Income (ttm)	-468.06M
Shares Out	65.80M
EPS (ttm)	-7.12
PE Ratio	n/a
Forward PE	3.56
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,991
Average Volume	118,992
Open	35.45
Previous Close	34.70
Day's Range	33.80 - 35.60
52-Week Range	22.70 - 50.80
Beta	-0.05
RSI	46.58
Earnings Date	Aug 26, 2025

About STO:BINV

BioInvent International AB (publ), a clinical-stage company, discovers, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company’s drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin’s lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 114
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: BINV

Financial Performance

In 2024, STO:BINV's revenue was 44.69 million, a decrease of -37.47% compared to the previous year's 71.46 million. Losses were -429.38 million, 30.0% more than in 2023.